Response to Comment on: Rizzo et al. Reduction of Oxidative Stress and Inflammation by Blunting Daily Acute Glucose Fluctuations in Patients With Type 2 Diabetes: Role of Dipeptidyl Peptidase-IV Inhibition. Diabetes Care 2012;35:2076–2082 | Zendy

Maria Rosaria Rizzo | Zendy; Michelangela Barbieri | Zendy; Raffaele Marfella | Zendy; Giuseppe Paolisso | Zendy

Open Access

Response to Comment on: Rizzo et al. Reduction of Oxidative Stress and Inflammation by Blunting Daily Acute Glucose Fluctuations in Patients With Type 2 Diabetes: Role of Dipeptidyl Peptidase-IV Inhibition. Diabetes Care 2012;35:2076–2082

Author(s) -

Maria Rosaria Rizzo,

Michelangela Barbieri,

Raffaele Marfella,

Giuseppe Paolisso

Publication year - 2012

Publication title -

diabetes care

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 6.636

H-Index - 363

eISSN - 1935-5548

pISSN - 0149-5992

DOI - 10.2337/dc12-1436

Subject(s) - medicine , diabetes mellitus , oxidative stress , type 2 diabetes , inflammation , dipeptidyl peptidase 4 , endocrinology

DeVries (1) was surprised that vildagliptin and sitagliptin groups reported different mean amplitude of glycemic excursions (MAGE) reduction because they have similar fasting and postprandial glucose levels and suggested reporting other measures of glucose variability to better understand these results.Indeed, a previous study evaluating the role of glycemic variability in type 2 diabetic patients has demonstrated that patients with similar mean glucose and postprandial glucose have a markedly different daily glucose profile with differences both in number and duration of excursions (2). The difference in MAGE reduction found in the two study groups …

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research